Join Aprea Therapeutics for a virtual event featuring Joseph P. Vacca, PhD, Medical Chemistry Expert and Consultant to Aprea Therapeutics, who will discuss the medicinal chemistry history, highly selective drug design, and preclinical findings of oral WEE1 inhibitor APR-1051. The event will also feature Eric J. Brown, PhD (University of Pennsylvania) who will discuss preclinical findings across the WEE1 inhibitor class. WEE1 is an enzyme involved in the DNA damage response pathway and is a validated oncology target.

APR-1051 is a potent and selective small molecule that has been designed to limit off-target toxicity. Aprea recently initiated the Phase 1 ACESOT-1051 trial evaluating APR-1051 as monotherapy treatment in patients with significant unmet medical need, including patients with Cyclin E over expression.

A live question and answer session will follow the formal presentations.